{"entity":{"id":"nct06855277","kind":"trial","name":"Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC","aka":["AcTFirst"],"tldr":"A phase 3 trial testing AAA817 in prostate cancer, now recruiting.","summary":"Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC is a phase 3 interventional study registered as NCT06855277, led by Novartis Pharmaceuticals, and recruiting on the registry. Official title: A Phase III, Open-label, Multi-centre, Randomised Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive Metastatic Castration Resistant Prostate Cancer. Planned enrolment is 940 participants (estimated). The study started in 2025-07-01 and primary completion is expected in 2028-09-29. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT06855277","url":"https://clinicaltrials.gov/study/NCT06855277"}],"tags":["ctgov-ingest"],"related":[],"cancers":["prostate","prostate-mcrpc"],"sections":[],"technologies":[],"targets":[],"drugs":["aaa817"],"companies":["novartis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06855277","phase":"3","setting":"A Phase III, Open-label, Multi-center, Randomized Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive Metastatic Castration Resistant Prostate Cancer","sponsor":"Novartis Pharmaceuticals","participation":[{"nct":"NCT06855277","source":"https://clinicaltrials.gov/study/NCT06855277","fetchedAt":"2026-10-07T16:55:09.829Z","studySha256":"b6533778dcb66c42311fa213cdb44b3dc02dd5d9d21000fb2f3161dcffd1cf0d","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-22","leadSponsor":"Novartis Pharmaceuticals","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"100 Years","sex":"MALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":940,"enrolmentType":"ESTIMATED","siteCount":100,"recruitingSiteCount":100,"countries":["Australia","Brazil","China","Hong Kong","India","Japan","Mexico","Singapore","South Korea","Taiwan","United Kingdom","United States"]}],"started":"2025-07-01","startedType":"actual","enrolled":940,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06855277/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"aaa817","kind":"drug","name":"AAA817","route":"/drugs/aaa817/"}],"company":[{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/"}]}}